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Objective: The objective of this study was to assess whether the Acute Physiology, Age, Chronic Health Evaluation II
(APACHE-II) score is a reliable predictor of 30-day mortality in the setting of adult patients with ventilator-dependent
respiratory failure (VDRF) who undergo tracheostomy.
Methods: This is a retrospective, single-institution study. Potential subjects were identiﬁed using the current procedural
terminology codes for the tracheostomy procedure and International Classiﬁcation of Diseases, 10th Revision, codes for VDRF.
APACHE-II scores were retrospectively calculated. Tracheostomies were performed in our population over an 18-month period
(November 2018 through April 2020). Our study population did not include patients with novel coronavirus. The primary
outcome was mortality at 30 days after tracheostomy.
Results: A total of 238 patients with VDRF who had a tracheostomy were included in this study. Twenty-eight (11.8%)
patients died within 30 days of tracheostomy. The mean (standard deviation) APACHE-II score was 22.5 (10.2) for patients
who died within 30 days of tracheostomy and 19.8 (7.4) for patients living within 30 days of tracheostomy (p = 0.30). Patients
with APACHE-II scores greater than or equal to 30 showed higher odds of death within 30 days of tracheostomy (odds ratio,
3.0; 95% CI, 1.14–7.89, p = 0.03).
Conclusion: An APACHE-II score of 30 and above is associated with mortality within 30 days of tracheostomy in patients
with VDRF. APACHE-II scores may be a promising tool for assessing risk of mortality in patients with VDRF after
tracheostomy.
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INTRODUCTION
Prolonged endotracheal intubation increases risk of
laryngeal injury in ventilator-dependent patients.1 For this
reason, a surgical airway in the form of a tracheostomy is
often pursued to minimize this risk. Tracheostomy plays a
large role in reducing risk of complications among survivors
of critical illness. Early tracheostomy has been shown to
improve patient-centric outcomes during critical illness,
including return to oral intake, ability to verbally communicate, and earlier participation in physical rehabilitation.2 It
has also been argued that tracheostomy reduces the risk of
post-intensive care syndrome (the long-term physical, cognitive, and mental health sequelae associated with prolonged
critical illness).3,4 In the age of the novel coronavirus pandemic, tracheostomy, which is associated with earlier ventilatory wean, may have an integral role in resource utilization,
allowing for more available ventilators, ICU beds, and staff.3
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and Neck Surgery is routinely consulted to evaluate patients
with ventilator-dependent respiratory failure (VDRF) for possible tracheostomy. Unfortunately, some patients who
undergo tracheostomy will not survive the critical illness for
which they have been hospitalized, raising the question of
whether it is possible to identify which patients may be at
higher risk for 30-day mortality after tracheostomy.
Kashlan et al. recently studied various patient factors associated with 30-day mortality after tracheostomy.5 Their study found that the presence of medical
comorbidities calculated using the Charlson comorbidity
index (CCI) was linked with mortality after tracheostomy,
with higher Charlson comorbidity index scores associated
with increased 30-day mortality post-tracheostomy.
Although the CCI provides predictive value about mortality risk in critically ill patients,6 it is based solely on medical comorbidities at the time of admission, omitting the
acute severity of the patient’s present illness. The objective of our study was to evaluate whether an acute illness
severity score, rather than a comorbidity index, could also
be used to predict 30-day mortality after tracheostomy.
The Acute Physiology, Age, Chronic Health Evaluation II (APACHE-II) score is the most widely utilized disease severity scale in intensive care units (ICUs) as
reported in the English-language medical literature.7 The
scoring system utilizes the worst values of 12 physiological variables, such as temperature, heart rate, Glasgow
Coma Scale score, and white blood cell count, during the
ﬁrst 24 hours of ICU admission (Table I). Additionally,
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TABLE I.
The Acute Physiology, Age, Chronic Health Evaluation (APACHE) II score.
Physiologic Variable*

+4

+3

+2

+1

0

+1

+2

+3

+4

Temperature ( C)

≥41

39–40.9

—

38.5–38.9

36–38.4

34–35.9

32–33.9

30–31.9

≤29.9

Mean arterial pressure (mmHg)

≥160

130–159

110–129

—

70–109

—

50–69

—

≤49

Heart rate (min 1)

≥180

140–179

110–139

—

70–109

—

55–69

40–54

≤39

Respiratory rate (min 1)

≥50

35–49

—

25–34

12–24

10–11

6–9

—

≤5

≥500

350–499

200–349

—

<200

—

—

—

—

—

—

—

—

>70

61–70

—

55–60

<55

Oxygenation (mmHg)
A-aDO2 if FiO2 ≥50%
FiO2 <50% using PaO2
Arterial pH

≥7.7

7.6–7.69

—

7.5–7.59

7.33–7.49

—

7.25–7.32

7.15–7.24

<7.15

Sodium (mmol/L)

≥180

160–179

155–159

150–154

130–149

—

120–129

111–119

≤110

Potassium (mmol/L)

≥7

6–6.9

—

5.5–5.9

3.5–5.4

3–3.4

2.5–2.9

—

<2.5

Creatinine (mg/dl)†

≥3.5

2–3.4

1.5–1.9

—

0.6–1.4

—

<0.6

—

—

Hematocrit (%)

≥60

—

50–59.9

46–49.9

30–45.9

—

20–29.9

—

<20

White blood count (1000/mm3)

≥40

—

20–39.9

15–19.9

3–14.9

—

1–2.9

—

<1

Glasgow Coma Scale (GCS)

Calculated as 15 minus actual GCS

Serum HCO3 (mmol/L)‡

≥52

32–40.9

22–31.9

—

18–21.9

15–17.9

<15

41–51.9

—

A = Total acute physiology score (APS) = Sum of all the physiologic variables.
B = Age points: add +0 for <44, +2 for 45–54, +3 for 55–64, +5 for 65–74, and +6 for ≥75.
C = Chronic health points: if previous history of severe organ system disease or immunocompromise, +2 for elective postoperative patients, +5 for
nonoperative or emergency postoperative patients.
APACHE II Score = A (APS) + B (Age) + C (Chronic).
*Based upon the worst variable in the past 24 hours.
†
Doubled if acute renal failure.
‡
If no arterial blood gas is available.

the scoring system incorporates an evaluation of the
patient’s chronic health and admission diagnoses.8
APACHE-II scores have been shown to be predictive of
overall mortality in mechanically ventilated patients.9
The maximum APACHE-II score is 71, though it is rare
for a patient to score higher than 55.8 A score of 25 indicates a predicted all-cause mortality of 50%, whereas a
score of over 35 represents a predicted all-cause mortality of 80%.10
In this study, APACHE-II scores were retrospectively calculated for patients with VDRF who had undergone tracheostomy between November 2018 and April
2020. These scores were then analyzed for the association
of score magnitude with patient mortality within 30 days
after tracheostomy. The primary hypothesis of our study
was that higher APACHE-II scores would be associated
with 30-day mortality after tracheostomy. Our aim was to
perform a proof-of-principle study to ascertain the utility
of a speciﬁc disease severity scoring system for assessing
risk of death within 30 days of tracheostomy within the
context of VRDF.
The family members and caregivers of critically ill
patients are often tasked with making difﬁcult decisions about the goals of care for their loved one. The
ultimate goal of our study is to determine whether
APACHE-II scores might be a useful guide for surgeons, intensivists, and the tracheostomy care team as
a whole when making the decision to pursue tracheostomy in critically ill patients. We sought to investigate
whether APACHE-II scores would be beneﬁcial to better counsel patients and families about tracheostomy
within the setting of VDRF.
Laryngoscope 00: 2022
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MATERIALS AND METHODS
The study was approved by the institutional review board,
with the need for consent waived. A total of 238 patients were
included in the study. Potential subjects were identiﬁed using
the current procedural terminology codes for the tracheostomy
procedure and International Classiﬁcation of Diseases, 10th
Revision, codes for VDRF. Patients who underwent tracheostomy
for other indications, such as obstructive sleep apnea, upper airway obstruction, head and neck cancer, etc., were excluded from
the study. All patients underwent open tracheostomy (none performed using the percutaneous method). Patients who underwent tracheostomy by services other than the Department of
Otolaryngology were excluded. APACHE-II scores were retrospectively calculated using the worst value (furthest from baseline/normal) within 24 hours of ICU admission. The study
patient population is composed of all patients at our institution
who received a tracheostomy for VDRF over an 18-month period
(November 2018 through April 2020). Of note, no patients in our
study population were diagnosed with novel coronavirus infection at the time of their hospitalization.
The distribution of APACHE-II scores within the two
groups (alive vs. deceased at 30 days) was examined using various plots. Normality assumptions of this distribution were violated, thus, a Wilcoxon rank sum test was used for comparison
between the two groups.
The odds ratio of mortality within 30 days of tracheostomy
was calculated for patients with APACHE-II scores above and
below a score of 30. As described by Knaus et al., the APACHE
scoring system does not deﬁne a speciﬁc low or high APACHE
score.8 Therefore, a score of 30 was chosen as our setpoint based
on the results of the original validation study, which demonstrated increased odds of mortality at this threshold.8 In that
study, Knaus et al. demonstrated that APACHE-II scores of 30–
34 had a 73% risk of mortality, compared with 55% in patients
with scores of 25–29. Additionally, an APACHE-II score of
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30 has been shown to meaningfully correlate with increased odds
of death in several published studies.11–13
Statistical signiﬁcance was set at p < 0.05. All analyses
were performed using SAS 9.4 (SAS Institute Inc, Cary, NC).

TABLE III.
Documented Cause of Death in Deceased Patients (N = 60).
Total (%)
Terminal wean in ICU
Within 30 days of tracheostomy

RESULTS
A total of 238 patients with VDRF who had a tracheostomy were included in this study (139 men and
99 women); the mean (standard deviation) age was 60.8
(14.6) years (Table II). Of these 238 patients, 28 (11.8%)
patients died within 30 days of tracheostomy. When
including deaths after 30 days, a total of 60 patients in
our study population did not survive their critical illness
(25.2%). Documented cause of death in our study population can be found in Table III. Of note, 29 patients
(12.2%) were either terminally weaned in the ICU or discharged to hospice/comfort care. Of those, 18 patients
were terminally weaned or transitioned to hospice/
comfort care within 30 days of tracheostomy (7.6%).
The mean (standard deviation) APACHE-II score
was 22.5 (10.2) for patients who died within 30 days of
tracheostomy and 19.8 (7.4) for patients living within
30 days of tracheostomy (p = 0.30). However, patients
with APACHE-II scores greater than or equal to
30 showed higher odds of death within 30 days of tracheostomy (odds ratio, 3.0; 95% CI, 1.14–7.89, p = 0.03). In
our study population, 28 patients had an APACHE-II
score of 30 or higher (see Fig. 1). No patient scored higher
than 43.
For patients who died beyond 30 days of tracheostomy, the mean (standard deviation) APACHE-II score
was 20.6 (5.7). There was no signiﬁcant difference in

TABLE II.
Descriptive Statistics of Study Population (N = 238).
Variable

Value

Age, year
Mean (SD)
Median (Q25, Q75)

60.8 (14.6)
63 (51, 71)

Sex, n (%)
Male

139 (58.4)

Mean age (SD)

60.9 (13.8)

Female
Mean age (SD)

99 (41.6)
60.5 (15.8)

Chronic health status, n (%)
Yes

68 (28.6)

No

170 (71.4)

30-day survival, n (%)
Yes

210 (88.2)

No

28 (11.8)

APACHE
Range

3–43

Mean (SD)

20.1 (7.8)

Median (Q25, Q75)

19.5 (15.0, 2)

APACHE = Acute Physiology, Age, Chronic Health Evaluation;
SD = standard deviation.
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16 (26.7%)
14 (23.3%)

Beyond 30 days of tracheostomy

2 (3.3%)

Discharge to hospice/comfort care

13 (21.7%)

Within 30 days of tracheostomy

4 (6.7%)

Beyond 30 days of tracheostomy
Cardiopulmonary arrest
Within 30 days of tracheostomy
Beyond 30 days of tracheostomy
Sepsis
Within 30 days of tracheostomy
Beyond 30 days of tracheostomy
Brain death
Within 30 days of tracheostomy
Beyond 30 days of tracheostomy

9 (15.0%)
12 (20%)
4 (6.7%)
8 (13.3%)
5 (8.3%)
2 (3.3%)
3 (5.0%)
1 (1.7%)
0 (0%)
1 (1.7%)

Cause unknown/not documented

13 (21.7%)

Within 30 days of tracheostomy

4 (6.7%)

Beyond 30 days of tracheostomy

9 (15%)

ICU = intensive care unit.

APACHE-II scores between patients who died within
30 days of tracheostomy and patients who died after
30 days (p = 0.38). The mean (standard deviation) timeto-death for patients who died within 30 days of tracheostomy was 14.9 (7.3) days, whereas patients who died
beyond 30 days after tracheostomy had a mean (standard) time-to-death of 52.5 (26.8) days (p < 0.001).

DISCUSSION
Illness severity scores, such as the APACHE-II system, can be helpful in guiding clinical practice. Proponents of these scoring systems argue that they are useful
in predicting outcomes and risk stratifying patients, as
well as widely used for clinical trial enrollment and as a
quality-improvement metric for ICU performance.14 With
the rise of the electronic medical record and advances in
information technology, illness severity scores have
become more widely incorporated into medical decisionmaking through the use of computerized clinical decision
support systems.15 Despite their perceived usefulness,
these systems often fail to be accepted into the daily clinical decision-making of physicians. Liberati et al. found
that physicians often view these systems as unreliable,
overwhelming, or even as a threat to physician autonomy.16 Our study presents an easy, efﬁcient, and potentially beneﬁcial application of the APACHE-II scoring
system during evaluation of patients with VDRF for
tracheostomy.
Perioperative mortality at 30 days remains a fundamental safety assessment for hospitals and the health care community, and it has been validated in numerous studies as a
consistent quality metric. The APACHE-II score is one of the
Marget et al.: APACHE-II and Mortality After Tracheostomy
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Fig. 1. Distribution of APACHE-II scores in study population

most widely used illness severity scores7 and has been validated in numerous studies.17 We chose to use the APACHEII score in our study over the more recent APACHE scoring
systems, such as the APACHE-III and APACHE-IV scores,
because the APACHE-II score remains more widely used in
ICUs. APACHE-II is also freely available and easily accessible online and on smartphone apps, such as MDCalc.18
The APACHE-II score is more widely used than the
Charlson comorbidity index7 and has been shown to be a
superior predictor of inpatient mortality.19 Quach et al.
postulated that the APACHE-II outperforms CCI because
the APACHE-II’s validation study only included ICU
patients, whereas the validation study of the CCI consisted of inpatients of all kinds.19 Our group theorizes
that the APACHE-II score may be a more holistic representation of the patient’s acute illness, though this was
not investigated in the present study. Future study is
needed to directly compare the predictive value of CCI
versus APACHE-II scores among patients who have
undergone tracheostomy.
In this observational study, we assessed the utility
of using the APACHE-II score as a tool to evaluate risk of
30-day mortality in patients with VDRF who received a
tracheostomy. Although patients who died within 30 days
of tracheostomy did not have a signiﬁcantly higher mean
APACHE-II score than patients who did not die, we
observed that APACHE-II scores greater than 30 are
indicative of a three-fold increased risk of death within
30 days of tracheostomy.
Our study has several limitations. As a retrospective
study, ﬁndings cannot be generalized to the population at
large. We assessed patients at one institution, and practices around treating VDRF and performing tracheostomy
at other institutions may result in different trends. Our
study included a small sample population, and larger prospective studies are warranted to conﬁrm the utility of
Laryngoscope 00: 2022
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APACHE-II as a predictor of mortality for a similar
patient population.
Our study population solely included patients who
had undergone open tracheostomies performed by the
Department of Otolaryngology; therefore, patients who
underwent percutaneous tracheostomy or tracheostomy
performed by other services were excluded. It is possible
that this may have resulted in a selection bias based
upon how patients are deemed candidates for open tracheostomy by our department. Although our criteria are
likely similar to others, there is a speciﬁc emphasis on
patient stability (stable vital signs, minimal pressor
requirements), minimal ventilator settings (generally,
FiO2 ≤50%, PEEP ≤8), and patient prognosis. However,
the overall mortality (25.2%) among all patients is
roughly equivalent to rates reported in other large studies, with typical estimates of 18%–25%.20 Additional data
that may affect overall survival, such as timing of tracheostomy, duration of ventilation prior to tracheostomy, and
ventilator settings, were not collected.
In our study population, 48.3% of patients who died
after tracheostomy were either terminally weaned in the
ICU or discharged to hospice/comfort care. This statistic
emphasizes the complexity of patient selection and the
imperfect ability of physicians (both surgeons and intensivists) to predict the course of critical illness. Additional
investigation into withdrawal of care after tracheostomy
is needed but beyond the scope of the present study. In
select circumstances, tracheostomy can be a palliative
measure at the end of life to reduce patient suffering.21
By only studying patients whose families consented
for tracheostomy and who underwent the procedure,
patients whose families did not consent for surgery (for
whatever reason) were excluded from the data. Furthermore, given the changing demographics of ICU
populations due to the COVID-19 pandemic, our results
Marget et al.: APACHE-II and Mortality After Tracheostomy

may not be generalizable to patients with prolonged intubation secondary to active COVID-19 infection. However, our
ﬁndings regarding the association of APACHE-II score magnitude and the odds of 30-day post-tracheostomy mortality
are compelling and warrant further investigation.
Although 30-day mortality continues to be an important quality metric for patients, surgeons, hospitals, and
payers, some have argued that this outcome measure
may underestimate the true risk of a procedure.22–24 In
our study population, there was no signiﬁcant difference
in the APACHE-II scores between those patients who
died within 30 days of tracheostomy and those who died
beyond 30 days. For patients and their families, the distinction between mortality before 30 days and after
30 days may be irrelevant.
The decision to pursue tracheostomy is often complex and has implications on both the hospital course and
future quality of life for critically ill patients. For many
patients, tracheostomy is the next step in advancing
toward a resolution of critical illness, while some patients
will unfortunately not survive the critical illness for
which they are hospitalized. In the past, pursuing tracheostomy was a binary choice led by the proceduralist in
consultation with family; however, the approach to the
procedure and its role in care pathways has evolved.
Quality-improvement initiatives, like the Global Tracheostomy Collaborative, seek to improve care through interdisciplinary education, patient and family involvement,
and data driven efforts.25 These endeavors have been
shown to signiﬁcantly improve quality, safety, and organizational efﬁciency, with the potential to produce dramatic cost savings for health systems as a whole.26
Multidisciplinary approaches to tracheostomy care have
been linked with signiﬁcant effects on individual patient
lives, through improved outcomes such as decreased time
to decannulation, reduced airway-related adverse events,
and greater adoption of speaking valve use.27 We hope
that the results of this study prove useful to multidisciplinary stakeholders in tracheostomy care.
Multidisciplinary approaches are now even more
crucial in the continued time of the COVID-19 pandemic.
Approaching tracheostomy in this patient population
requires consideration of many aspects, including
the physical and biopsychosocial factors of the patient,
the resources of the health system, and the safety of
health care workers, patients, and patient families.28 A
10–21-day period has been suggested as the window for
tracheostomy in COVID-19 afﬂicted patients where all of
the aforementioned factors may be considered and best
balanced.28,29 The pandemic unfortunately only adds difﬁculty in the challenge of caring for patients who may
require tracheostomy.
Tracheostomy has widespread implications for
patients and families. The choice to consent to tracheostomy can be challenging and unclear for families of critically ill patients. Even in the best of circumstances,
caring for a loved one with a tracheostomy can be full of
daunting challenges, which can range considerably, from
frustrations with coordinating home care and supplies to
the dangers of inadequate emergency airway training.30
Families may have a wide range of concerns at the time
Laryngoscope 00: 2022

of initial tracheostomy consultation: how the tracheostomy will affect the patient’s course of illness, whether
the tracheostomy may prolong or even increase the suffering of their loved one, or whether their loved one may succumb to their critical illness despite the tracheostomy. It
is our desire that this study can further aid clinicians in
guiding patients’ family members and caregivers when
making the decision to consent to tracheostomy.

CONCLUSION
An APACHE-II score of 30 and above is a potentially
useful clinical indicator of increased risk of mortality
within 30 days of tracheostomy in patients with VDRF.
This tool may prove a valuable resource for ICU physicians and surgeons who are considering tracheostomy for
patients with VDRF. APACHE-II scores may also be of
beneﬁt to health care providers as they help to assist family and caregivers in making complex decisions about the
goals of care for their loved one.
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